153 related articles for article (PubMed ID: 35220592)
1. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.
Teng F; Zhang W; Wang W; Chen J; Liu S; Li M; Li L; Guo W; Wei H
Biopharm Drug Dispos; 2022 Apr; 43(2):76-85. PubMed ID: 35220592
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
6. Impact of Donor and Recipient
Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
[No Abstract] [Full Text] [Related]
7. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.
Jalil MH; Hawwa AF; McKiernan PJ; Shields MD; McElnay JC
Br J Clin Pharmacol; 2014 Jan; 77(1):130-40. PubMed ID: 23738951
[TBL] [Abstract][Full Text] [Related]
11. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
Lu Y; Xu L; Cui J; Shen S; Li X
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
13. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study.
Liu J; Guo YP; Jiao Z; Zhao CB; Wu H; Li ZR; Cai XJ; Xi JY
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):453-466. PubMed ID: 32170643
[TBL] [Abstract][Full Text] [Related]
17. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetic study of tacrolimus and
Qu J; Bian R; Liu B; Chen J; Zhai J; Teng F; Guo W; Wei H
Front Pharmacol; 2022; 13():956166. PubMed ID: 36188616
[No Abstract] [Full Text] [Related]
[Next] [New Search]
